Business UpdateJun 15, 2026, 04:33 PM
Dyadic C1 Platform Sees Accelerated Interest for Ebola & Commercial Use
AI Summary
Dyadic International announced accelerated interest in its proprietary C1 biomanufacturing platform, driven by global Ebola preparedness efforts and growing commercial adoption. The C1 platform is highlighted for its rapid, scalable, and cost-effective manufacturing capabilities for vaccines and antibodies, crucial during infectious disease outbreaks. The company is also expanding its commercialization strategy across life sciences, food, nutrition, and industrial markets with its C1 and Dapibus™ platforms, targeting significant market opportunities.
Key Highlights
- Dyadic's C1 biomanufacturing platform is seeing accelerated interest for Ebola preparedness activities.
- The C1 platform can progress from gene sequence to purified antigen or antibody in approximately 15 days.
- Collaborations include Scripps Research, CEPI, Fondazione Biotecnopolo di Siena, and the European Vaccines Hub.
- Commercial milestones include launching recombinant human albumin and DNase I, and commercializing recombinant bovine chymosin.
- Advancing recombinant transferrin and growth factor products for cell culture media and cultivated meat.
- C1 and Dapibus™ platforms target over $25 billion in addressable market opportunities across multiple sectors.
Price Impact
More from DYAI